Cargando…

MicroRNAs: short non-coding players in cancer chemoresistance

Chemoresistance is one of the main problems in the therapy of cancer. There are a number of different molecular mechanisms through which a cancer cell acquires resistance to a specific treatment, such as alterations in drug uptake, drug metabolism and drug targets. There are several lines of evidenc...

Descripción completa

Detalles Bibliográficos
Autores principales: Donzelli, Sara, Mori, Federica, Biagioni, Francesca, Bellissimo, Teresa, Pulito, Claudio, Muti, Paola, Strano, Sabrina, Blandino, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451970/
https://www.ncbi.nlm.nih.gov/pubmed/26056584
http://dx.doi.org/10.1186/2052-8426-2-16
Descripción
Sumario:Chemoresistance is one of the main problems in the therapy of cancer. There are a number of different molecular mechanisms through which a cancer cell acquires resistance to a specific treatment, such as alterations in drug uptake, drug metabolism and drug targets. There are several lines of evidence showing that miRNAs are involved in drug sensitivity of cancer cells in different tumor types and by different treatments. In this review, we provide an overview of the more recent and significant findings on the role of miRNAs in cancer cell drug resistance. In particular, we focus on specific miRNA mechanisms of action that in various steps lead from drug cell sensitivity to drug cell resistance. We also provide evidence on how miRNA profiling may unveil relevant predictive biomarkers for therapy outcomes.